Denali Therapeutics Average Rating is 'Buy' with a Target Price of $37.40

Summary

According to a FactSet survey, the average analyst rating for Denali Therapeutics is ‘Buy’, with an average target price of $37.40.Trading View

Impact Analysis

This event is at the company level as it pertains specifically to Denali Therapeutics. The main impact here is on the investor sentiment towards Denali Therapeutics. The updated target price of $37.40 represents a slight decrease from the previously reported target price of $39.44 on February 11, 2025.Trading View This could indicate a minor shift in analyst outlook or expectations regarding the company’s future performance. Investors may need to consider this new target price alongside other analyst reports. For instance, Jefferies Financial Group raised its target price for Denali from $40.00 to $45.00 on March 2, 2025, reflecting a more optimistic view.Market Beat The existence of differing target prices and the ‘Buy’ rating suggest potential investment opportunities, but also the necessity for investors to conduct a thorough analysis of why these target prices have changed.